JSJie-Yan Shen

Jie-Yan Shen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jie-Yan Shen has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • An Wang

    Department of Cardiology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China

    3 shared publications
  • Jun Tong

    Department of Cardiology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China

    3 shared publications
  • Binqian Ruan

    Department of Cardiology, Punan Hospital, Shanghai, China

    2 shared publications
  • Chuanxue Wan

    Department of Cardiology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China

    2 shared publications
  • Mengqi Chen

    Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Yuexiu District, Guangzhou, China

    2 shared publications
  • An Wang

    Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian Road, Shanghai 200127, China

    1 shared publication

Latest Publications

  • Open Access

    Development and validation of novel prognostic hepatic-cardiac index and hemodynamic prediction models in pre-capillary pulmonary hypertension patients

    by Jun Tong, An Wang, Chuanxue Wan, Mengqi Chen, Qi Zhuang, Binqian Ruan, Jinyao Jiang, Menghui Yang, Jieyan Shen

    Pulmonary arterial hypertension (PAH) is a life-threatening disorder marked by progressive elevation of pulmonary vascular resistance and ultimate right heart failure. Its diagnosis and risk stratification largely depend on invasive right heart catheterization (RHC). This study aimed to integrate routine laboratory and echocardiographic data to develop a novel multi-organ prognostic indicator and construct non-invasive hemodynamic estimation prediction models. This was a multi-center retrospective study enrolling a total of 44 routine laboratory and echocardiographic indices of pre-capillary pulmonary hypertension. Key prognostic variables were screened using Least absolute shrinkage and selection operator-Cox (LASSO-Cox) regression and random survival forest (RSF) analysis. The novel composite index was constructed based on correlation analysis with hemodynamic parameters. Prognostic performance was evaluated using Cox regression, Time-Dependent Receiver Operating Characteristic (time-dependent ROC) curve analysis, stratified analysis, and decision curve analysis (DCA). Linear prediction models for invasive hemodynamic parameters were established using variable selection and internal validation. A total of 179 patients with pre-capillary pulmonary hypertension were included. Using LASSO-Cox and random survival forest, 13 core prognostic variables were identified, including total bilirubin (TB) and B-type natriuretic peptide (BNP). The novel hepatic-cardiac index--TBI (log [total bilirubin × BNP]) was constructed and validated as an independent prognostic factor (HR=1.64, 95%CI: 1.287–2.09, P=0.0001). Predictive efficacy at 36 months was significantly higher for TBI (area under the curve, AUC = 0.777) than for BNP (AUC = 0.723, P = 0.021 with false discovery rate [FDR] adjustment). Stratified analysis confirmed that TBI remained prognostic in patients with BNP levels between 200 and 800 pg/mL (χ 2 =7.075, P = 0.008). Additionally, non-invasive linear prediction models for mean pulmonary arterial pressure(mPAP), pulmonary vascular resistance (PVR), and PVR×CO (cardiac output) were established with moderate accuracy (R 2 =0.575, 0.507, 0.523, respectively) Integration of laboratory and echocardiographic parameters enables improved non-invasive evaluation in pulmonary hypertension. The novel hepatic-cardiac index (TBI, log[TB×BNP]) serves as a robust and independent prognostic biomarker. Routine non-invasive indices can reliably estimate key hemodynamic parameters in clinical practice.

  • Open Access

    Prognostic value of atherogenic index of plasma in pulmonary hypertension

    by Meng-Qi Chen, An Wang, Chuan-Xue Wan, Bin-Qian Ruan, Jun Tong, Jie-Yan Shen

    Background: The atherogenic index of plasma (AIP) is a brand-new lipid parameter that has been used to assess various cardiovascular events. This study aimed to investigate the prognostic value of AIP in patients with pulmonary hypertension (PH).Methods: This retrospective study was conducted at Shanghai Jiao Tong University School of Medicine affiliated Renji Hospital, and included data from 125 PH patients treated during 2014–2018. The endpoint events of this study were clinical worsening outcomes. PH patients include those from group 1 and group 4. AIP was determined as the logarithm of the blood triglycerides ratio to high-density lipoprotein cholesterol.Results: The 1-year, 3-year, and 5-year incidence rates of clinical worsening outcomes in PH patients in this study were 20.0, 44.8, and 54.4%, respectively. The median age of the PH patients was 38.00 years, with females accounting for 90.4%. After controlling for multivariable factors, the results of Cox regression analysis indicated that AIP was an independent predictor of adverse outcomes with a hazard ratio and 95% confident interval (CI) of 2.426 (1.021–5.763). The positive linear relationship of AIP was evaluated using restricted cubic spline analysis. Kaplan–Meier curves showed a significantly higher events rate in patients with AIP ≥ 0.144 compared to those with AIP < 0.144 (p = 0.002). Four potential prognostic variables, including AIP, were identified by LASSO regression to construct a nomogram. Compared to the model minus AIP, the AUC of the nomogram displayed a non-significant improvement (0.749 vs. 0.788, p = 0.298). In contrast, the results of net reclassification improvement (0.306, 95% CI: 0.039–0.459, p < 0.001) and integrated discrimination improvement (0.049, 95% CI: 0.006–0.097, p = 0.020) demonstrated significant enhancements in the predictive ability of the model when AIP was added to the clinical model.Conclusion: AIP is an independent predictor of long-term clinical worsening in PH patients, and its inclusion in prognostic models could improve risk stratification and management.


  • Open Access

    Prognostic Role of Lymphocyte-to-C-Reactive Protein Ratio in Patients with Pulmonary Arterial Hypertension

    by Meng-Qi Chen, Chuan-Xue Wan, Jun Tong, An Wang, Bin-Qian Ruan, Jie-Yan Shen

    Background: Inflammation plays a critical role in the prognosis of patients with pulmonary arterial hypertension (PAH). The lymphocyte-to-C-reactive protein ratio (LCR), as a novel inflammatory marker, has not been studied in patients with PAH. The objective of this study was to investigate the prognostic value of the LCR in patients with PAH. Methods: A retrospective cohort study was conducted on 116 patients with PAH diagnosed in Renji Hospital, School of Medicine, Shanghai Jiao Tong University, from January 2014 to December 2018. The primary outcome was a composite endpoint that included lung transplantation, rehospitalization for PAH, and all-cause death. The LCR is the ratio of the blood lymphocyte count to the C-reactive protein concentration. Results: A total of 116 patients with PAH were included in this study, with an average age of 41.53 years; 92.2% were female, and the event rate was 57.8%. Restricted cubic spline analysis confirmed a linear association between the LCR and the risk of clinical worsening events. Multivariate Cox proportional hazards analysis showed that the LCR was significantly negatively associated with clinical worsening events, with hazard ratios and 95% confidence intervals of 0.772 (0.614–0.970). The Kaplan–Meier curve showed that event-free survival decreased significantly when the LCR was less than 1.477. LASSO regression selected four potential predictors, including the LCR, to construct a nomogram. The nomogram had a high predictive strength, with an area under the ROC curve of 0.805 (0.713–0.896). The calibration curves and decision curve analysis indicated that the nomogram had good predictive performance and the ability to guide clinical management. Conclusions: The LCR is a valuable prognostic marker for predicting long-term clinical events in patients with PAH, and the nomogram incorporating the LCR could effectively stratify risk and guide clinical decision making.